Sobi strengthens focus and increases investments in late-stage development in Haematology and Immunology
- Intended reorganisation of R&D to increase focus and investment in late-stage development
- Plans to establish centres of excellence in Sweden and Switzerland
- The new focus of the R&D organisation would lead to annual savings of SEK?200?300? M in 2020 to be reallocated to late-stage development. Costs of around SEK?100?200?M relating to the reorganisation and redundancies will be charged in 2019.
Paula Treutiger | ||
Head of Communication & Investor Relations | ||
+46?733?666 599 | ||
paula.treutiger@sobi.com | ||
Linda Holmstr?m | ||
Corporate Communication & Investor Relations | ||
+46?708?734 095 | ||
linda.holmstrom@sobi.com | ||